A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Non-hematologic Malignancies Clinical Trial

Official title:

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01705483
• Other study ID #: 9853-CL-0101
• Status: Terminated
• Phase: Phase 1
• Start date: August 28, 2012
• Est. completion date: June 11, 2014

Study information

• Verified date: May 2019
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Description:

This is a two part study. Part 1 will test increasing dose levels of ASP9853 in combination with docetaxel. Part 2 will test increasing doses of ASP9853 combined with paclitaxel. Each part will determine the maximum tolerated dose and recommended Phase 2 dose for ASP9853 in combination with each taxane. Preliminary evidence of antitumor activity of ASP9853 in combination with docetaxel or with paclitaxel also will be explored.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: June 11, 2014
• Est. primary completion date: June 11, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must have a histologically or cytologically confirmed incurable, locally advanced, or metastatic non-hematologic malignancy that has progressed or failed to respond to regimens or therapies known to provide clinical benefit

• Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status = 1

• Subject must have recovered from the effects of prior systemic antineoplastic or radiation therapy(s) to = Grade 1 severity or to subject's baseline values, excluding alopecia

• Subject agrees not to participate in another interventional study while on treatment

Female subject must be either:

Of non child bearing potential:

• post-menopausal (defined as at least 1 year without any menses) prior to Screening or

• documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening)

Or, if of childbearing potential:

• must have a negative serum pregnancy test at Screening and

• must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days after final study drug administration

Acceptable forms include:

• Established use of oral, injected or implanted hormonal methods of contraception.

• Placement of an intrauterine device (IUD) or intrauterine system (IUS).

• Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps) with spermicidal

• foam/gel/film/cream/suppository

• Female subject must not donate ova starting at Screening and throughout the study period and for 28 days after final study drug administration.

• Male subject must not donate sperm starting at Screening and throughout the study period and for 28 days after final study drug administration.

• Subject with adequate bone marrow, renal, and hepatic function at baseline

Exclusion Criteria:

• Subject has received more than 3 prior cytotoxic agent-containing regimens

• Subjects with prior anaphylactic or hypersensitivity reaction to prior taxane therapy

• Subject with symptomatic central nervous system (CNS) metastases or leptomeningeal involvement

• Subjects who received treatments with any of the following:

• Systemic chemotherapy within 21 days

• Nitrosoureas or mitomycin C within 42 days

• Radiotherapy to = 25% of hematopoietically active bone marrow within 21 days

• Subject had major surgical procedure within 28 days or anticipates need for major surgical procedure during course of the study

• Female subjects who are breastfeeding at Screening or during the study period and for 28 days after final study drug administration.

• Subject with peripheral neuropathy > Grade 1 at baseline

• Subject with known hepatitis B surface antigen (HBsAg) positive status; or known or suspected active hepatitis C infection; or known human immunodeficiency virus (HIV) positive

• Subject with malabsorption syndrome or disease or condition significantly affecting gastrointestinal function

• Subject with significant or uncontrolled cardiac, renal, hepatic or other systemic disorders, or significant psychological conditions at baseline

• Subject with clinically significant electrocardiogram (ECG) abnormalities on 12 lead ECG performed within 14 days before start of study drug

• Subject who has received strong inhibitors or inducers of CYP3A4 within two weeks prior to start of study treatment and while on study

• Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half lives, whichever is longer, prior to the initiation of Screening

Related Conditions & MeSH terms

• Neoplasms
• Non-hematologic Malignancies
• Pharmacokinetics of ASP9853

Intervention

Drug:
• ASP9853
oral
• Docetaxel
intravenous (IV)
• Paclitaxel
Taxol

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Barbara Ann Karmanos Cancer Center	Detroit	Michigan
United States	Sarah Cannon Research Institute	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) physical examinations, and vital signs		Duration of study (24 months) to Final Study Visit, up to = 30 days after last dose of ASP9853
Secondary	Pharmacokinetics (PK) Profile for ASP9853: AUC24, AUClast, AUCinf, Cmax, Ctrough, tmax, t1/2, CL/F, and Vz/F	Area under the plasma concentration curve at 24 hours (AUC24), AUC from time zero to time of last measurable concentration (AUClast), AUC with the last concentration extrapolated to infinity (AUCinf), Maximum concentration (Cmax), Trough plasma concentration (Ctrough),Time to attain Cmax (Tmax), Apparent terminal elimination half-life (T1/2), Oral clearance (CL/F), and Volume of distribution during the terminal phase (Vz/F)	Parts 1 and 2, Cycle 1, Day 1: Pre-dose and 9 times within the 24 hour period following ASP9853 dosing; Days 8 and 15: pre-dose, Cycles 2 + , Day 1: predose
Secondary	Pharmacokinetics (PK) Profile for Docetaxel: AUC24, AUClast, AUCinf, Cmax, tmax, t1/2, CL, and Vd ss	Clearance (CL), Distribution volume, steady state (Vd ss)	Part 1, Cycle 1, Day 1: Pre-dose and 9 times within the 24 hour period
Secondary	Pharmacokinetics (PK) Profile for Paclitaxel: AUC24, AUClast, AUCinf, Cmax, tmax, t1/2, CL, and Vd ss		Part 2: Cycle 1: Day 1: Pre-dose and 9 times within the 24 hour period
Secondary	Objective response rate (ORR)	The proportion of subjects with a complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.1	Treatment start to final Study Visit , up to 24 months
Secondary	Duration of response (DOR)		CR or PR response until last study visit at which a tumor assessment or an assessment of clinical disease progression is performed, up to 24 months

External Links

•   Link to results on the Astellas Clinical Study Results website